
On Friday, a European agency adopted two positive opinions for Merck & Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab).
One opinion recommends approval of a new subcutaneous (SC) administration route and a solution for injection formulation. If approved, Keytruda SC could be administered in one minute every three weeks (395 mg) or two minutes every six weeks (790 mg).